01. June 2018.
The leader in the pharmaceutical market of Serbia and the region, one of ten largest exporters in Serbia - the company Hemofarm, celebrated 58 years of successful business operation. Anniversary of the company which started its development journey from a small pharmaceutical plant in Vršac and became the international company with 3500 employees and exporting to 38 countries, was celebrated by the traditional reception for the employees, jubilee award holders and pensioners.
Over the course of last year, Hemofarm accomplished new business successes and became the main hub of the STADA Group, within which it operates, for the central European markets (Poland, Czech Republic and Slovakia), whereby it expanded the area of its competence to total 13 countries of central and South-East Europe. The construction of the state-of-the-art Packaging Centre in Vršac, an investment worth 21.6 million euros, was successfully completed, while a new plant for production of sterile nasal sprays (SNUP) was constructed within Hemomont factory in Podgorica.
Since August 2006, when Hemofarm became a part of German Stada Group, about 300 million euros have been invested in modernization of operations, equipment and new plants, and new investments are also planned. ’I am proud that we have maintained the leadership position in Serbia, Bosnia and Herzegovina and Montenegro and that we are making strong progress in other markets. To be the market leader is the goal of every company, but to keep the leadership position is probably even harder. Nevertheless, decades of successful operation have taught us how to become and remain the best – we are constantly striving to modernization, and we are ready to adjust at the same time, to the requirements of the local markets and global business conditions. We are putting an effort to be new and different and that’s why I can say that Hemofarm has the wisdom of a mature man, and the enthusiasm of a teenager’, says Ronald Seeliger, CEO of Hemofarm, at the occasion of company anniversary.
Future plans of Hemofarm are closely related to further strengthening and internationalization of operations of Stada, which intends to become one of five largest generic producers in the world.
